We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+8.65%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$6.63B
AUM Growth
+$825M
Cap. Flow
+$471M
Cap. Flow %
7.11%
Top 10 Hldgs %
82.61%
Holding
140
New
29
Increased
38
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.1M
2
INCY icon
Incyte
INCY
+$10.5M
3
DNLI icon
Denali Therapeutics
DNLI
+$8.99M
4
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$7.86M
5
ALBO
Albireo Pharma Inc
ALBO
+$7.61M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$33.5M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.4M
3
RXDX
Ignyta, Inc.
RXDX
+$11.1M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$10.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.07M

Sector Composition

Rank Sector Weight
1 Consumer Staples 43.26%
2 Consumer Discretionary 19.67%
3 Healthcare 17.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BUFF
1
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
$2.87B 43.26%
87,460,875
– –
WW
2
DELISTED
WW International
WW
$1.3B 19.67%
29,443,300
– –
LXRX icon
3
Lexicon Pharmaceuticals
LXRX
$1.03B
$576M 8.68%
58,274,650
+756,673
+1% +$7.86M
BAC icon
4
CALL
Bank of America
BAC
$433B
$171M 2.58%
5,800,000
-4,050,000
-41% -$112M
IBM icon
5
CALL
IBM
IBM
$215B
$123M 1.85%
836,800
+627,600
+300% +$91.3M
C icon
6
CALL
Citigroup
C
$216B
$112M 1.68%
1,500,000
+1,200,000
+400% +$88.7M
WFC icon
7
CALL
Wells Fargo
WFC
$257B
$91M 1.37%
1,500,000
+850,000
+131% +$48M
GILD icon
8
CALL
Gilead Sciences
GILD
$166B
$89.5M 1.35%
1,250,000
+1,000,000
+400% +$75.9M
ALXN
9
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$77.7M 1.17%
+650,000
New +$79.2M
NKTR icon
10
CALL
Nektar Therapeutics
NKTR
$2.36B
$65.7M 0.99%
73,333
+33,333
+83% +$19.7M
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$38.4B
$57.2M 0.86%
450,000
+200,000
+80% +$25.1M
BMY icon
12
CALL
Bristol-Myers Squibb
BMY
$130B
$55.2M 0.83%
900,000
+250,000
+38% +$15.6M
GS icon
13
CALL
Goldman Sachs
GS
$293B
$51M 0.77%
200,000
– –
INCY icon
14
Incyte
INCY
$25.6B
$47.4M 0.71%
500,000
+100,000
+25% +$10.5M
BABA icon
15
CALL
Alibaba
BABA
$275B
$34.5M 0.52%
+200,000
New +$35.8M
XBI icon
16
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$33.9M 0.51%
+400,000
New +$33.5M
AGN
17
CALL
DELISTED
Allergan plc
AGN
$32.7M 0.49%
200,000
– –
XLRN
18
DELISTED
Acceleron Pharma
XLRN
$31.8M 0.48%
750,000
+50,000
+7% +$1.88M
VRTX icon
19
CALL
Vertex Pharmaceuticals
VRTX
$124B
$30M 0.45%
+200,000
New +$29.6M
ONC
20
BeOne Medicines Ltd
ONC
$34B
$29.3M 0.44%
300,000
+75,000
+33% +$6.87M
AGIO icon
21
Agios Pharmaceuticals
AGIO
$2.09B
$28.6M 0.43%
500,000
+50,000
+11% +$3.15M
BLUE
22
DELISTED
bluebird bio
BLUE
$26.7M 0.4%
11,580
+1,158
+11% +$2.35M
MS icon
23
CALL
Morgan Stanley
MS
$323B
$26.2M 0.4%
500,000
+200,000
+67% +$10.1M
ALNY icon
24
CALL
Alnylam Pharmaceuticals
ALNY
$38.4B
$25.4M 0.38%
+200,000
New +$25.1M
NKTR icon
25
Nektar Therapeutics
NKTR
$2.36B
$23.9M 0.36%
26,667
-56,666
-68% -$33.5M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2017 Portfolio in Review

As of Q4 2017, Artal Group held 140 positions worth $6.63B, up 14% from $5.81B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group deployed $471M of net new capital in Q4 2017, opening 29 new positions and adding to 38 existing holdings. Its largest new stake was Denali Therapeutics: 500,000 shares worth $7.82M.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Nektar Therapeutics, an estimated $33.5M trimmed.

  • Artal Group's largest Q4 2017 buy was Denali Therapeutics: 500,000 shares worth $7.82M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q4 2017, an estimated $25.1M increase.
  • Artal Group's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $33.5M.
  • Artal Group fully exited BioMarin Pharmaceuticals in Q4 2017, selling an estimated $17.4M.
  • Artal Group's ten largest holdings make up 83% of its $6.63B portfolio in Q4 2017.
  • Artal Group opened 29 new positions and closed 21 in Q4 2017.
  • Artal Group's portfolio value rose 14% quarter-over-quarter to $6.63B.

Based on Artal Group's 13F filing for Q4 2017, filed 9 Feb 2018.